Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Novartis Femara Gets Priority Review; 1st-Line Use For AstraZeneca Arimidex

This article was originally published in Pharmaceutical Approvals Monthly

  • News
  • Pharmaceutical Approvals Monthly

Executive Summary

Novartis could see FDA action by January on its Femara sNDA for first-line treatment of advanced breast cancer in postmenopausal women. The application for the aromatase inhibitor was filed July 11 and received a priority review designation on Sept. 11, ten days after the approval of AstraZeneca’s AI Arimidex for the same indication.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

NGGT Progresses First US Gene Therapy Trials For Rare Conditions

'We Are Not Waiting To Be Replaced': Medical Affairs Pros Take On GPT-4o

Japan Reimburses Zolbetuximab, To Cut Price Of Imfinzi, Others

Korea’s Clinical Trial Approvals Up 10%, But Still Below Pandemic Peak

See All
UsernamePublicRestriction

Register

PS001208

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By